Biosynex SA (EPA:ALBIO)
1.240
+0.005 (0.40%)
May 16, 2025, 4:46 PM CET
Biosynex Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 4.69 | 20.17 | 87.17 | 132.03 | 36.84 | Upgrade
|
Short-Term Investments | 5 | 6 | - | - | - | Upgrade
|
Cash & Short-Term Investments | 9.69 | 26.16 | 87.17 | 132.03 | 36.84 | Upgrade
|
Cash Growth | -62.96% | -69.99% | -33.98% | 258.43% | 1368.38% | Upgrade
|
Accounts Receivable | 7.1 | 10.65 | 14.7 | 25.27 | 11.49 | Upgrade
|
Other Receivables | 10.39 | 5.84 | 14.09 | 6.08 | 5.78 | Upgrade
|
Receivables | 17.49 | 16.49 | 28.79 | 31.35 | 17.27 | Upgrade
|
Inventory | 32.67 | 38.21 | 37.67 | 31.15 | 32.55 | Upgrade
|
Prepaid Expenses | - | 2.93 | 1.43 | 1.05 | - | Upgrade
|
Other Current Assets | -0 | 1.9 | 3.35 | 2.27 | - | Upgrade
|
Total Current Assets | 64.39 | 91.35 | 159.61 | 198.78 | 87.53 | Upgrade
|
Property, Plant & Equipment | 14.85 | 11.94 | 6.38 | 3.44 | 2.36 | Upgrade
|
Long-Term Investments | 0.39 | 0.47 | 2.57 | 3.28 | 1.98 | Upgrade
|
Goodwill | - | 91.54 | 60.91 | 46.24 | 29.27 | Upgrade
|
Other Intangible Assets | 113.01 | 39.8 | 25.95 | 5.89 | 1.28 | Upgrade
|
Long-Term Deferred Charges | - | - | - | - | 0.63 | Upgrade
|
Other Long-Term Assets | 2.05 | 6.63 | 4.93 | 11.31 | 3.02 | Upgrade
|
Total Assets | 194.69 | 241.73 | 260.34 | 268.94 | 126.07 | Upgrade
|
Accounts Payable | 16.31 | 15.07 | 14.99 | 18.73 | 19.59 | Upgrade
|
Accrued Expenses | 16.65 | 6.19 | 6.62 | 7.64 | 6.64 | Upgrade
|
Short-Term Debt | - | 0.24 | 0.04 | 0.04 | 0.05 | Upgrade
|
Current Portion of Long-Term Debt | - | 5.6 | 49.48 | 0.15 | 5.96 | Upgrade
|
Current Portion of Leases | - | 0.55 | 1.41 | - | - | Upgrade
|
Current Income Taxes Payable | - | 0.01 | 1.73 | 19.81 | 13.65 | Upgrade
|
Current Unearned Revenue | - | 0.51 | 0.22 | 1.94 | 0.07 | Upgrade
|
Other Current Liabilities | - | 9.17 | 8.36 | 12.45 | 3.11 | Upgrade
|
Total Current Liabilities | 32.97 | 40.82 | 83.86 | 61.32 | 49.08 | Upgrade
|
Long-Term Debt | 62.63 | 58.28 | 1.15 | 34.08 | 9.75 | Upgrade
|
Long-Term Leases | - | 1.29 | - | 1.04 | - | Upgrade
|
Other Long-Term Liabilities | 18.6 | 17.02 | 8.43 | 4.69 | 0.95 | Upgrade
|
Total Liabilities | 114.19 | 117.41 | 93.45 | 101.14 | 59.78 | Upgrade
|
Common Stock | 1.08 | 1.08 | 1.03 | 1.11 | 0.92 | Upgrade
|
Additional Paid-In Capital | 25.6 | 25.6 | 25.6 | 47.27 | 27.9 | Upgrade
|
Retained Earnings | - | 55.31 | 77.08 | 130.92 | 31.46 | Upgrade
|
Comprehensive Income & Other | 53.9 | 42.49 | 58.83 | -11.5 | 6.01 | Upgrade
|
Total Common Equity | 80.58 | 124.48 | 162.53 | 167.81 | 66.29 | Upgrade
|
Minority Interest | -0.08 | -0.17 | 4.37 | - | - | Upgrade
|
Shareholders' Equity | 80.5 | 124.32 | 166.9 | 167.81 | 66.29 | Upgrade
|
Total Liabilities & Equity | 194.69 | 241.73 | 260.34 | 268.94 | 126.07 | Upgrade
|
Total Debt | 62.63 | 65.96 | 52.08 | 35.31 | 15.77 | Upgrade
|
Net Cash (Debt) | -52.94 | -39.8 | 35.1 | 96.72 | 21.07 | Upgrade
|
Net Cash Growth | - | - | -63.71% | 359.13% | - | Upgrade
|
Net Cash Per Share | -4.92 | -3.72 | 3.41 | 9.31 | 2.36 | Upgrade
|
Filing Date Shares Outstanding | 10.77 | 10.76 | 10.25 | 10.32 | 10.04 | Upgrade
|
Total Common Shares Outstanding | 10.77 | 10.76 | 10.25 | 10.32 | 9.15 | Upgrade
|
Working Capital | 31.42 | 50.53 | 75.75 | 137.45 | 38.45 | Upgrade
|
Book Value Per Share | 7.48 | 11.57 | 15.85 | 16.26 | 7.24 | Upgrade
|
Tangible Book Value | -32.43 | -6.86 | 75.67 | 115.67 | 35.73 | Upgrade
|
Tangible Book Value Per Share | -3.01 | -0.64 | 7.38 | 11.21 | 3.90 | Upgrade
|
Buildings | - | 0.09 | - | - | - | Upgrade
|
Machinery | - | 19.27 | 10.58 | 6.37 | 3.05 | Upgrade
|
Construction In Progress | - | 0.02 | 0.03 | - | 1.02 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.